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Abstract: Oral chemotherapy represents a major patient-centric advancement in therapy convenience.
However, ownership of safe and correct administration of these agents requires significant patient
education. To address this challenge, an in-person pharmacist-led oral chemotherapy education
clinic in gastrointestinal oncology patients within an academic medical center was created and
assessed. In this pilot program, a medication-specific quiz was administered to patients before
and after education performed by a pharmacist to assess patient understanding of their new
oral chemotherapy. A five-question satisfaction survey was also administered at the conclusion
of the pharmacist clinic visit. Primary outcome was the percentage difference between pre-and
post-education quiz scores. Secondary outcomes included patient satisfaction, time to treatment
initiation, and number of pharmacist interventions. Frequencies and medians were used to describe
categorical and continuous variables, respectively. Of the 18 patients analyzed, 50% were male
and median age was 59.5 years. Approximately 28% had colon cancer, and 61% were treated with
capecitabine. The median post-education scores improved from a pre-education score of 75% to
100%. Overall, seventeen of the eighteen patients responded with “strongly agree” to all satisfaction
survey statements. An in-person oncology pharmacist-led oral chemotherapy education session
demonstrated an improvement in patients’ understanding of their new oral chemotherapy treatment.
Keywords: oral chemotherapy; oral oncolytic; oncology pharmacy; education; patient satisfaction;
gastrointestinal oncology; specialty pharmacy
1. Introduction
Oral chemotherapy agents have been used in the treatment of cancer for decades. However,
it has not been until recently that the market has seen a dramatic expansion in the number of oral
chemotherapy agents approved and incorporated into clinical practice guidelines. The use of these
agents in clinical practice is an appealing treatment option for patients due to enhanced convenience
when compared with intravenous agents.
While oral chemotherapy is more convenient, the use of these agents poses several challenges.
There is an inevitable challenge with ensuring adherence to the regimen, safe administration, as well
as appropriate storage and handling methods when these tasks are completed by the patients and/or
their caregiver. Additionally, many of these agents require complex dosing schedules, as some are only
indicated to be taken on specific days of a cycle, and it is the patient’s responsibility to follow the regimen
accurately. Adherence to necessary lab monitoring is another challenge. Generally, administration
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of intravenous chemotherapy is preceded by appropriate laboratory monitoring. Prescribers of oral
chemotherapy rely on patients to be compliant with obtaining necessary laboratory tests.
Due to these inherent difficulties, thorough patient education is of utmost importance to
ensure accurate administration and adherence. While education can be performed via telephone
for convenience, its success can be limited by various factors including, though not limited to,
environmental distractions, reliable phone service, and the ability to reach the patient by phone. These
factors can also lead to delays in treatment initiation if clinicians must make multiple phone calls to
obtain necessary information such as insurance data, financial documents, and signatures on financial
assistance paperwork. In-person educations can eliminate some of these limitations, as environmental
distractions can be minimized and when scheduled, the provider is guaranteed the ability to reach
the patient. This scheduled visit bypasses the inefficiencies caused by missed calls/messages, missing
signatures, paperwork, and documentation and avoids a reliance on fax, email, or the postal service.
Additionally, the provider can observe the patient’s body language which can provide additional
insight into the patient’s level of comprehension. In-person education also provides an opportunity to
give patients printed educational materials, medication calendars and adherence tools, as well as the
potential to utilize demonstration kits as available to reinforce the information.
In fact, there are several published reports of pharmacist-led oral chemotherapy management
programs created to utilize these concepts. Patel, et al. published their study of a pharmacist-led oral
chemotherapy monitoring program in prostate cancer patients and reported a significant increase in
interventions, lab adherence, and overall duration of time patients spent on each therapy [1]. Lam and
Cheung evaluated an oncology pharmacist-managed oral anticancer therapy program for patients
with chronic myeloid leukemia and reported higher adherence rates compared to usual care and
approximately ten interventions per patient [2]. Muluneh et al. published their results including
increased treatment comprehension, adherence, and interventions [3]. Given these positive findings,
a pilot program was created to evaluate the effectiveness of a pharmacist-led oral chemotherapy
clinic, which aimed to provide in-person educations to patients with gastrointestinal (GI) malignancies
starting an oral chemotherapy agent.
2. Materials and Methods
Starting in October 2019, pharmacists on the Advanced Therapies Pharmacy (ATP) team at
Indiana University Health Simon Cancer Center scheduled GI oncology patients starting a new oral
chemotherapy treatment for a 45-minute, face-to-face education visit with an oncology pharmacist.
All subjects gave their authorization of consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Institutional Review Board (IRB).
At the beginning of the education visits, patients were introduced to the pilot program and were
informed that their participation, quiz scores, and survey results would be collected as data. Next, they
were introduced to a four-question drug-specific quiz (see Appendix A). Questions on this quiz varied
from proper administration technique to side effect management and dosing. The medication quiz
was utilized to compare the difference between quiz scores prior to their education session, when they
would have only previously received education from their physician, and their scores after education
with a pharmacist. After the patients completed the pre-session quiz, the pharmacist reviewed
important counseling points about the medication including but not limited to, proper administration
technique, dosing schedule, storage and handling, common side effects and management, and a review
of any drug interactions identified during medication reconciliation. The teach-back method was
utilized to ensure that the patient properly understood all important counseling points throughout the
education session. After all of the patient’s questions were answered, the patient repeated the same
four question quiz to assess comprehension. After reviewing the quiz with the patient, the patient was
asked to participate in a five-statement satisfaction survey to gain understanding of the usefulness of
the counseling session. This survey was completed in private prior to leaving clinic and given back to
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the pharmacist in an envelope to minimize potential response bias. Responses to survey statements
were designed as a score range of 1–4 with 1 being “strongly agree” and 4 being “strongly disagree.”
The highest satisfaction score that can be achieved if a patient responded with “strongly agree” to
every statement would be a score of 5. See Appendix B for details on survey statements and scoring
system. Our goal was to have a score of ≤2 on each question to indicate that patients found the visit to
be helpful overall.
The primary outcome of this pilot program was percentage difference between pre-and
post-education quiz scores. Secondary outcomes included patient satisfaction, time to treatment
initiation, and number of pharmacist interventions. Frequencies and medians were used to describe
categorical and continuous variables, respectively. Mode was utilized to assess patient satisfaction
survey questionnaires.
3. Results
Between November 2019 and January 2020, 18 patients were seen by an oncology pharmcist in
the oral chemotherapy clinic and were included in this pilot program. The median age was 59.5 years
(range, 36 to 76 years) with males representing 50% of patients. The most common GI malignancy
was colon cancer (28%) followed by rectal cancer and hepatocellular carcinoma (HCC), 22% each. The
baseline characteristics of all patients are shown in Table 1.
Table 1. Patients baseline characteristics (N = 18).
Characteristic Value
Age (years) Median (range) 59.5 (36–76)
Sex, male no. (%) 9 (50.0)
GI malignancy diagnosis, no. (%)
Appendix adenocarcinoma
Carcinoma of unknown primary
Cholangiocarcinoma
Colon cancer
Gastrointestinal stromal tumor
Hepatocellular carcinoma
Rectal cancer
1 (6.0)
2 (11.0)
1 (6.0)
5 (28.0)
1 (6.0)
4 (22.0)
4 (22.0)
The most commonly prescribed oral chemotherapy agent was capecitabine (61%) followed by
lenvatinib (17%). Prescribed oral chemotherapy agents for all patients are shown in Figure 1.
Pre- and post-education quiz questionnaires were administered to all patients. The median
pre-education quiz score was 75% (range, 50% to 100%). After receiving pharmacist education during
oral chemotherapy clinic visit, the median quiz score increased to 100%.
All patients completed the five-question satisfaction survey administered at the conclusion of
their oral chemotherapy clinic visit. Patient satisfaction score mode was 5 (range, 5 to 6). Patient
responses to the satisfaction survey are shown in Table 2. Patients responded with “strongly agree” to
all survey statements except for statement 1 where one patient responded with “agree.” Overall, 98.9%
of patients “strongly agreed” with the satisfaction statements.
The median time to treatment initiaiton was 5.5 days (range, 1 to 29 days). One patient required
manufacturer-supplied oral chemotherapy due to high out-of-pocket copay costs, and drug procurement
time was 29 days. Half of the oral chemotherapy agents were filled internally at Indiana University
Health Advanced Therapies Pharmacy. The remaining prescribed agents were externally filled based
on patients’ commercial insurance requirements. A summary of all outcomes is shown in Table 3.
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Figure 1. Newly prescribed oral chemotherapy for patients with gastrointestinal (GI) malignancy in
the pilot program.
Table 2. Patient responses to the satisfaction survey.
Survey Statements Strongly Agree (%) Agree (%) Disagree (%) Strongly Disagree (%)
Statement 1 1 94.40 5.60 0 0
Statement 2 2 100 0 0 0
Statement 3 3 100 0 0 0
Statement 4 4 100 0 0 0
Statement 5 5 100 0 0 0
1 The pharmacist helped me understand why I am taking my new cancer medication. 2 The pharmacist made sure
that my medicines are safe (possible side effects and avoiding drug interactions). 3 The pharmacist helped me
understand the best way to take my cancer medication. 4 After speaking with my pharmacist, I feel more confident
about taking my cancer medication. 5 I would recommend my pharmacist to a family member or friend.
Table 3. Outcomes of a Pharmacist-Led Oral Chemotherapy Clinic Pilot Program in GI Oncology at
Indiana University Health—Simon Cancer Center.
Outcome Measures Results
Medication-specific quiz scores, median (%)
Pre-education
Post-education
75
100
Patient satisfaction score, mode (range) 5 (5–6)
Time to treatment initiation in days, median (range) 5.5 (1–29)
Oncology pharmacists provided at least one medicaton intervention related to the newly prescribed
oral chemotherapy in each of the 18 patients. There were a total of 20 pharmacist inteventions in the
overall population. The complete list of oncology pharmacist interventions are described in Table 4.
The most common pharmacist intervention was identification of drug interactions (40%) followed by
identification of baseline tests required prior to initiating specific oral chemotherapy agents (40%).
Table 4. Clinical oncology pharmacist interventions related to the newly-prescribed oral chemotherapy
for patients in the pilot program.
Oncology Pharmacist Interventions Number (%)
Drug interaction identification
Baseline monitoring or laboratory test needed
Medication dose change
Supportive care recommendation
Identification of errors during transcription
8 (40.0)
8 (40.0)
2 (10.0)
1 (5.0)
1 (5.0)
Pharmacy 2020, 8, 46 5 of 7
4. Discussion
With the increase in FDA approved indications for oral chemotherapy agents and an emphasis
on integrated specialty pharmacy services at academic institutions, oncology pharmacists are in a
unique position to positively impact patient care through personalized education sessions during
clinic visits. While other studies evaluating the implementation of oral chemotherapy programs exist,
this is the first to analyze the impact of in-person pharmacist-led education in patients starting an oral
chemotherapy agent for any GI malignancy.
Historically, published data in the GI oncology population has largely focused on capecitabine
therapy. In 2007, Macleod et al. reported on their combined nursing and pharmacy oral capecitabine
monitoring program in the United Kingdom and reported high patient satisfaction (≥85%) [4]. While in
2011, Simons et al. highlighted increased adherence to capecitabine with a multidisciplinary approach
including pharmacists [5]. Hend et al. published the effect of telephone-based follow up on adherence,
efficacy, and toxicity of oral capecitabine in May 2019 [6]. Within our institution, telephone-based
education and monitoring has been the standard of care since the development of our integrated
specialty pharmacy in 2015. While it has been proven that regular follow up with patients on oral
chemotherapy has a positive impact on adherence, the limitations of telephone encounters compared
to in-person visits for initial patient education has not been explored.
Outside of capecitabine-specific literature, there is no study to date evaluating oral chemotherapy
education for all oral therapies in the GI oncology population. With the continually evolving oral
treatment options in advanced hepatocellular carcinoma, colorectal cancer, and other GI malignancies,
our team recognized the utility of completing a study involving all oral agents utilized in patients with
GI malignancies.
The results of our primary outcome suggest that in-person pharmacist education, in addition
to the patient’s physician visit, improves patient understanding of their oral chemotherapy. When
developing this pilot program, patient satisfaction was a priority for our team. We wanted to ensure
patients were receiving detailed and meaningful education sessions without negatively impacting
the time they must spend in the cancer center. The GI oncology patient population already spends
a significant amount of time coming for follow up visits, lab monitoring, infusions, and potential
inpatient admissions. By adding on an additional 45-minute education session, we were concerned we
could negatively contribute to their already stressful schedules.
In 2018, Muluneh et al. reported patient satisfaction among patients included in an integrated,
closed-loop, pharmacist-led oral chemotherapy program [3]. The authors concluded that 97.8% of the
patients in this study reported the teaching provided to them was “good” or “excellent.” While this
data is encouraging, we could not extrapolate it to our patient population since we planned for them to
return back into clinic for a separate clinic visit specifically with a pharmacist. We worried this added
clinic visit could negatively impact patient satisfaction, but our results suggest otherwise. With 98.8%
of patients strongly agreeing with the statements in the patient satisfaction survey, we are confident
that an added clinic visit to speak with an oncology pharmacist is both beneficial for education and
satisfactory to the patient.
Additionally, we found a decrease in time to initiation when patients came back for additional
in-person education with an oncology pharmacist. Retrospective data from the GI oncology oral
chemotherapy patient population in quarter one of 2019 suggested a turn-around time of 6.5 days. We
were able to trim a day off patient time to initiation by having an additional touch point with them in
clinic. We speculate that this could be due to the ability to have them fill out any financial assistance
paperwork in person instead of waiting to scan, fax, or mail paperwork back and forth between the
clinic and the patient.
Furthermore, this program sought to identify aspects of oral chemotherapy treatment where
pharmacists made a large impact outside of the education session. In order to do this, we documented
any interventions the oncology pharmacist made when chart reviewing a new oral chemotherapy
patient. In doing this, we identified multiple drug-drug interactions, missing baseline labs or tests,
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necessary changes to the medication dosing, and omitted supportive care requirements. Most notably,
we found we needed to intervene on baseline monitoring in 40% of the patients included in this pilot
program. We have identified this as an area of need for further development, and we plan to discuss
collaborative practice agreements to assist with lab monitoring.
This pilot program yields positive results in patient education quiz grades, patient satisfaction
scores, and improved time to treatment initiation. However, this is a very small sample size compared
to the overall volume of our cancer center. Additionally, we provided the medication education
quizzes immediately after the patient received counseling on their new treatment. Moving forward,
we hope to continue data collection in a larger volume of patients across multiple malignancies. We
also plan to explore alternative times to administer the pre- and post- education quizzes to see if we
can determine retention.
5. Conclusions
GI oncology patients at our institution showed improved understanding of their new oral
chemotherapy after receiving in person education from an oncology pharmacist. These results suggest
there is an opportunity to improve patient understanding with the addition of a formalized oral
chemotherapy education clinic led by oncology pharmacists.
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Appendix A
Example of a Pre- and Post-Pharmacist Education Medication Specific Quiz
Capecitabine (Xeloda)
1. How many times a day is capecitabine taken?
A. 1
B. 2
C. 3
D. 4
2. How do you take capecitabine in relation to food/meals?
A. Capecitabine should be taken on an empty stomach
B. Capecitabine should be taken with a snack
C. Capecitabine should be taken within 30 minutes of completing a meal
D. Capecitabine can be taken with or without food, it does not matter
3. Which over the counter medication could you take if you develop diarrhea while on capecitabine?
A. Imodium (loperamide)
B. Pepto-Bismol (bismuth subsalicylate)
C. Prilosec (omeprazole)
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D. Metamucil (psyllium fiber)
4. Which of the following ingredients in a skin cream may help prevent Hand-Foot Syndrome
caused by capecitabine?
A. Glycerin
B. Hyaluronic acid
C. Aloe
D. Urea
Appendix B
Table A1. Pharmacist-Led Oral Chemotherapy Clinic Patient Satisfaction Survey.
Statement Score (1–4)
The pharmacist helped me understand why I am taking my new cancer medication.
The pharmacist made sure that my medicines are safe (knowing possible side effects and
avoiding drug interactions).
The pharmacist helped me understand the best way to take my cancer medication.
After speaking with my pharmacist, I feel more confident about taking my cancer
medication.
I would recommend my pharmacist to a family member or friend.
Please rate how you feel about the following statements on a scale of 1 to 4. (1: Strongly agree 2: Agree 3: Disagree
4: Strongly disagree).
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